In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cortendo names new chair

This article was originally published in Scrip

Executive Summary

Cortendo, a global biopharmaceutical company focused on orphan endocrine disorders, has appointed John H Johnson chair of its board of directors and named Richard Kollender a director. These appointments, proposed by the nomination committee, were approved by shareholders during the Extraordinary General Meeting on 17 March. Mr Johnson has more than 30 years of biopharmaceutical industry experience at organizations including Johnson & Johnson, Lilly, ImClone and Pfizer. He is currently a member of the board of directors of Cempra Pharmaceuticals, Histogenics, Portola Pharmaceuticals, and Sucampo Pharmaceuticals. He previously served as chair of Dendreon and Tranzyme Pharma, and also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts